Skip to main content
MYGNMyriad Genetics, Inc.Sell4.1·$6.29
MYGN · Decision

Should you buy Myriad Genetics (MYGN)?

Updated

Model-generated analysis — not investment advice. Not a registered investment advisor. Past performance does not guarantee future results. How we score · Editorial policy

Show full disclosure ▾

About TrendMatrix. TrendMatrix is a publisher of general securities research and market commentary. We publish on a regular schedule. All content is the same for every subscriber in a tier — we do not provide personalized investment advice and we do not take into account any individual subscriber's financial situation, investment objectives, risk tolerance, tax situation, or holdings.

Not investment advice. TrendMatrix is not a registered investment adviser. Our content is for informational and educational purposes only. Consult your own licensed investment adviser, broker, or tax professional before making any investment decision.

Conflicts and positions. People who build TrendMatrix, or entities they control, may hold positions, long or short, in securities it covers, and may trade them at any time. Positions are not disclosed individually. Verdicts are generated by an automated model applied by the same rules to every covered stock, and are not adjusted for any position held by the people who build TrendMatrix. We do not accept payment from issuers for coverage.

No paid promotion. TrendMatrix does not accept payment from any issuer, broker, or third party in exchange for coverage of any security.

No fiduciary duty. No fiduciary, advisory, or agency relationship is created between you and TrendMatrix by reading our content or subscribing to our service.

Performance. Past performance is not indicative of future results. Performance figures reflect the published model only and do not reflect any individual subscriber's actual results.

Methodology · Editorial policy & full disclaimer

Verdict
SELL
Score
4.1/10
Price
$6.29
Entry / Take Profit (TP) / Stop Loss (SL)
— / — / $5.85

Engine methodology range

Range computation requires sufficient peer-comparable data; available for tickers with peer_count ≥3.

What the engine is tracking

  • Rule Of Forty Failure→Stable
  • Sharp Revenue Decline→Stable
  • Late Cycle Momentum Risk↑Improving
  • +1 more pillar — see the Why tab for full reasoning

→ Full pillar scorecard with all 4 pillars + per-dimension breakdown

When this thesis breaks

Falsifiable conditions per pillar — any one trip warrants review independent of price action. Engine-derived; not personalized advice.

Falsifying conditions — when triggered, the corresponding pillar's thesis is invalidated.

  • P1Sharp Revenue Decline

    Trip ifRevenue growth exceeds -10% YoY within the next 2 quarters.

  • P2Rule Of Forty Failure

    Trip ifRule of 40 score exceeds 0 within the next 4 quarters.

  • P3Late Cycle Momentum Risk

    Trip ifMomentum score falls below 3.5, confirming a downtrend, within 2 months.

  • P4Modest Insider Selling

    Trip ifInsider selling as a percent of market cap exceeds 0.1% within the next 90 days.

How the engine reached this verdict

1. Direct answer

TrendMatrix's engine output for Myriad Genetics, Inc. (MYGN) is SELL_IF_HOLDING with medium conviction, score 4.1/10 at $6.29. The reward-to-risk gate failed, producing a SELL engine output.

2. What would change the verdict

The dominant failed gate is reward-to-risk (NEGATIVE). SELL flips back toward HOLD if reward-to-risk recovers above its threshold AND a co-failing gate also clears. The strongest-cleared gate today is MOMENTUM:6.3>=5.5.

3. What the engine sees

On the bear side: V8: Target reached (-37.9% upside); Quality below floor (3.6 < 4.0); Value-trap signals (2/5): Margin compression (op margin 4.0%), Material insider selling (5 sells, 0.12% of cap). Active engine warnings: V8: Target reached (-37.9% upside), Quality below floor (3.6 < 4.0), Value-trap signals (2/5): Margin compression (op margin 4.0%), Material insider selling (5 sells, 0.12% of cap).

4. Entry, target, and stop

The engine's exit framework anchors to a tactical sell band near $6.29, with structural invalidation at $5.85. The asymmetric R:R against a reversal hypothesis is -2.53 — the upside scenario exists, but it requires multiple structural gates to flip; the downside scenario requires only one more disappointment. The engine's sizing output: AVOID at this asymmetry level (no fresh-capital deployment).

For the full 10-dimension breakdown + V9 gate detail: Why TrendMatrix rates MYGN — 10-dimension breakdown →

Bear case

  • ▸V8: Target reached (-37.9% upside)
  • ▸Quality below floor (3.6 < 4.0)
  • ▸Value-trap signals (2/5): Margin compression (op margin 4.0%), Material insider selling (5 sells, 0.12% of cap)
Home › Stocks › MYGN › Buy or sell?